



# Tasrif Pharmaceutical Announces Grant of US Patent for Humanized Monoclonal Antibodies against the Poliovirus Receptor

USA, August 30, 2021 /EINPresswire.com/ -- Tasrif Pharmaceutical announces the grant of a US Patent related to its proprietary humanized monoclonal antibodies against the poliovirus receptor (a.k.a. CD155). The poliovirus receptor (PVR) is overexpressed on many malignancies including cancers of the brain, breast, colon and pancreas. Tasrif Pharmaceutical's lead molecule, TSRF 786C is a potential best-in-class fully humanized IgG4 (S241P) monoclonal antibody against PVR.

Preclinical studies have shown that TSRF 786C has high affinity and specificity for PVR, low immunogenicity and a low risk of infusion reaction. TSRF 786C is currently being developed for the modulation of the DNAM 1-CD155-TIGIT Axis and blockade of the PVR-TIGIT checkpoint. Immunotherapeutics based on TSRF 786C, which include Bispecifics, ADCs, T-cell engagers and CAR-T cells, are in discovery. Tasrif Pharmaceutical's humanized monoclonal antibodies against PVR have promise for targeted cancer immunotherapy. A US CIP and PCT are also pending.

## About TSRF 786C

TSRF 786C is a fully humanized monoclonal antibody (IgG4 S241P) under preclinical development for the treatment of brain and systemic cancers that express PVR.

## About Tasrif Pharmaceutical, LLC

Tasrif Pharmaceutical is a preclinical stage company that is a privately owned LLC incorporated in New York. Tasrif Pharmaceutical's mission is to improve and prolong the lives of cancer patients.

## Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, including declarations regarding expectations that involve substantial risks and uncertainties. In some cases, one can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "anticipates," "believes," "predicts," "projects," "intend", "potential best" or "continue", although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and

the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

## Contact

Tasrif Pharmaceutical, LLC  
tasrifpharmaceutical.org  
info@tasrifpharmaceutical.com

---

This press release can be viewed online at: <https://www.einpresswire.com/article/549915558>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.